News Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer Staff September 11, 2023 Iframe sync Post navigation Previous: EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023Next: Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference More Stories Brain Clinical Trial Concussion News PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting and Director Resignation Staff August 28, 2025 Healthcare News Pharmaceutical Sharps Technology, Inc. Closes Over $400 Million Private Placement, Launching Solana Digital Asset Treasury Strategy Staff August 28, 2025 Healthcare News Movano Health Granted Listing Extension by Nasdaq Staff August 28, 2025
